3Das B, Sarkar C. Is the sarcolemmal or mitochondrial K (ATP) channel activation important in the antiarrhythmic and cardioproteetive effects during acute ischemia/reperfusion in the intaet anesthetized rabbit model [J]. Life Sei, 2005,77(11):1226-1248.
4Stice JP, Lee JS, Pechenino AS, et al. Estrogen, aging and the cardio- vascular system [J]. Future Cardiol, 2009,5(1):93-103.
5Bradford PA. Extended-spectrum beta-lactamases in the 21stcentury: characterization,epidemiology, and detection of this important resistance threat [J]. Clin Microbiol Rev,2001,14(4):933-951.
6Nadal A, Alonso-Magdalena P, Soriano S, et al. The pancreatic betacell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes [J]. Mol Cell Endocrinol,2009,304(1- 2):63-68.
7Neuwirth C, Madec S, Siebor E, et al. TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate:new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3 [J]. Antimicrob Agents Chemother,2001,45(12):3591-3594.
8Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat [J]. Clin Microbiol Rev,2001,14(4):933-951.
9Vakulenko S, Golemi D. Mutant TEM beta-lactamase producing resistance to cef tazidime, ampicillins,and beta-lactamase inhibitors [J]. Antimicrob Agents Chemother,2002,46(3):646-653.
10van Marum RJ.Current and future therapy in Alzheimer's disease [J]. Fundam Clin Pharmacol,2008,22(3):265-274.
